Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00267917
First received: December 21, 2005
Last updated: October 28, 2013
Last verified: October 2013

December 21, 2005
October 28, 2013
January 2006
February 2006   (final data collection date for primary outcome measure)
The primary endpoint is the percentage of lung deposition achieved with natural inhaler technique compared with supervised optimal administration. [ Time Frame: up to 6 weeks ] [ Designated as safety issue: No ]
The primary endpoint is the percentage of lung deposition achieved with "natural" inhaler technique compared with supervised "optimal" administration.
Complete list of historical versions of study NCT00267917 on ClinicalTrials.gov Archive Site
  • Central lung zone deposition [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Intermediate lung zone deposition [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Peripheral lung zone deposition [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Ratio of peripheral lung zone to central lung zone deposition [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Oropharyngeal deposition [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • FEV1 15, 30 and 60 minutes post-administration (safety only) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
The "natural" inhalation technique and supervised "optimal" inhalation techniques will be compared for Respimat® inhaler and the MDI in terms of: o Central lung zone deposition o Intermediate lung zone deposition o Peripheral lung zone deposition
Not Provided
Not Provided
 
Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
A Randomised Open Label, Four Way, Cross-over Scintigraphic Evaluation of the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Poor MDI Technique.

The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD and known poor MDI inhalation technique following inhalation of Berodual? delivered via the Respimat? inhaler and Berodual? delivered via an HFA-metered dose inhal er achieved with their "natural" inhalation technique compared with taught "optimal" technique.

This is a single dose, randomised, active-controlled, four period, open-label cross-over trial in ad ult patients with COPD who have demonstrated a poor MDI technique. Berodual? (fenoterol hydrobromide 50 ?g + ipratropium bromide 20 ?g) will be delivered via the Respi mat? inhaler on two test days and via the MDI on two test days. Test days with no instruction on correct usage will occur prior to the test days with taught techniq ue, so that the patient's own technique will not be influenced by recent instruction.

Each device will thus first be used with no instructions on correct device use provided. On these no instruction test days each device will be demonstrated and patients will be allowed time to practis e on their own with a placebo device. The second time each device is used full instructions will be provided on the correct usage with pat ients practising with placebo either from the Respimat? inhaler or from the MDI until they are judge d competent. On these two test days the Respimat? or MDI inhalers will be fired by the investigator one second after the patient has started to inhale. Thus on Test Days 1 and 2 patients will use their own natural inhalation technique without receiving any instruction on correct usage. On Test Days 3 and 4 patients will use a supervised optimal techn ique having received instruction on correct usage and with the investigator firing the device.

The primary analysis will be carried out using the Sign Test. This is a non-parametric analysis in w hich no assumptions are made about the shape of the distribution of the responses from the Respimat? inhaler and from the MDI under the null hypothesis.

Study Hypothesis:

The null hypothesis is that poor technique has the same effect on the Respimat? and MDI devices. The alternative hypothesis is that poor technique has a differe nt effect on the Respimat? inhaler than on the MDI. This means that under the null hypothesis the median of the differences between the Respimat? inhaler and MDI pairs is zero i.e. the differences are equally lik ely to be positive or negative. Under the alternative hypothesis the median of t he differences between the Respimat? inhaler and MDI pairs is not zero i.e. the frequencies of the positive and negative signs are different.

Comparison(s):

Baseline comparability will be achieved by the use of a cross-over trial design with every patient receiving all four treatments and by ensuring at each test da y that baseline lung function is within 15% of the value obtained at the first t est day, pre-dose FEV1 is < 65% of predicted value and patients have abstained f rom inhaled bronchodilators for at least 4 hours prior to the visit. Treatment s equence will not be fitted as a term in the analysis of variance models.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Pulmonary Disease, Chronic Obstructive
  • Asthma
  • Device: Berodual Respimat
  • Device: Berodual HFA-MDI
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
13
February 2006
February 2006   (final data collection date for primary outcome measure)

Inclusion criteria:

COPD patients: FEV1 less or equal 65% pre FEV1 less or equal 70% of FVC

Exclusion criteria:

Patients with any upper respiratory infection in the past 14 days prior to the s creening visit (visit 1) Patients with any unstable or life-threatening cardiac arrhythmia

Both
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00267917
215.1365
Not Provided
Not Provided
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Study Coordinator B.I. Pharma GmbH & Co. KG
Boehringer Ingelheim
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP